12:20 PM EDT, 05/09/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We keep our 12-month target price of $130, valuing GL shares at 9x our '26 operating EPS estimate of $14.50, versus their one year average forward multiple of 8.2x and a peer average of 9x. We lower our '25 EPS estimate by $0.25, to $13.50, after GL reported Q1 2025 operating EPS of $3.07, up from $2.78, but missing our $3.32 estimate and consensus of $3.24. We keep our '25 and '26 revenue growth forecast of 3% to 7%, largely reflecting an expected 3% to 6% rise in life premiums and a 2% to 6% rise in health premiums. Q1 revenue grew 5% with premium growth of 3% in life insurance and 8% in health insurance. Underwriting income increased 4% Y/Y, driven by a 9% rise in life underwriting margins, partially offset by a 10% decline in health insurance margins. At current levels, we view the shares, currently trading at 9x our '25 EPS estimate, as fairly valued versus peer and historical averages.